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The symptom of low mood in the prodromal stage of
mild cognitive impairment and dementia: a cohort
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ABSTRACT
Objective To investigate the symptom of low mood as
a predictor of mild cognitive impairment (MCI) and its
progression to dementia, taking into account: (i) MCI
severity, (ii) time of assessment and (iii) interaction with
other factors.
Methods 764 cognitively healthy elderly subjects living
in the community, from the Kungsholmen Project.
Participants were assessed by direct interview to detect
low mood. Subjects were then followed for 6 years to
identify those who developed MCI. People with incident
MCI were followed for a further 3 years to assess
progression to dementia.
Results People with low mood at baseline had
a 2.7-fold (95% CI 1.9 to 3.7) increased risk of
developing MCI at follow-up. The association was
stronger for amnestic MCI (aMCI: HR 5.8; 95% CI 3.1 to
10.9) compared with global cognitive impairment (other
cognitive impairment no dementia, oCIND: HR 2.2; 95%
CI 1.5 to 3.3). ApoE-34 interacted with low mood in
a synergistic fashion, increasing the risk of aMCI,
while no interaction with psychiatric, vascular,
frailty related or psychosocial factors was observed. Low
mood at baseline, as opposed to low mood co-occurring
with MCI, was associated with a 5.3-fold (95% CI
1.2 to 23.3) increased risk of progression to
dementia in aMCI. In contrast, no association was found
in oCIND.
Conclusion Low mood was more strongly associated
with aMCI than with global cognitive impairment.
Progression towards dementia was predicted only by low
mood manifest in the prodromal stage of MCI. These
findings indicate that low mood is particularly prominent
in the very early stages of cognitive decline.
INTRODUCTION
Depression is the most studied neuropsychiatric
feature of mild cognitive impairment and its asso-
ciation with cognitive deterioration has been
shown both cross sectionally and longitudinally.1
Prevalence of depression is higher in mild cognitive
impairment (MCI) and dementia than in cogni-
tively healthy subjects.2 Subclinical syndromes of
depression and isolated depressive symptoms are
more common than clinical depression in both MCI
and dementia. Interestingly, the most prevalent
symptom of depression in MCI is low mood
whereas in dementia apathy is predominant.1
Longitudinally, depressive symptoms in cognitively
healthy persons have been consistently associated
with the development of MCI.3e7 In contrast,
studies on the progression of MCI towards
dementia have produced conﬂicting evidence. Out
of 10 studies,4 8e16 three found that depressive
symptoms increased the risk of progressing to
dementia4 14 16; two reported an association only in
women or for isolated symptoms12 13; three found
no association10 11 15; and two recent studies
reported that the presence of depressive symptoms
decreased the risk of developing dementia.8 9
The discrepancy between studies on MCI devel-
opment and studies on MCI progression may have
alternative explanations. First, depressive symp-
toms may have a different role in different stages of
the cognitive decline process. Speciﬁcally, symp-
toms of depression that are the expression of
underlying neurodegenerative pathology17 may be
prominent during the transition between healthy
cognition and initial cognitive impairment but lose
their importance in more advanced stages of
cognitive decline. Thus depressive symptoms may
be differentially related to MCI types of different
severity that represent different stages of the
dementing process. In amnestic MCI (aMCI),18 19
for instance, memory deﬁcits are present in the
background of otherwise preserved global cognitive
functioning whereas in other deﬁnitional cate-
gories, such as other cognitive impairment no
dementia (oCIND),20 21 cognitive functioning is
globally compromised although not yet to a degree
sufﬁcient to fulﬁl the criteria for a diagnosis of
dementia. Therefore, oCIND can be interpreted as
a more advanced stage of cognitive impairment
compared with aMCI.
Secondly, most studies investigating the
progression of MCI to dementia have focused on
depressive symptoms co-occurring with MCI.
Indeed, if low mood is an early feature of dementia
related neuropathology, its onset should precede
the stages when cognitive impairment becomes
manifest, ﬁrst as MCI and later as dementia. When
MCI or dementia is detectable, depressive symp-
toms could also result from a subjective reaction to
the cognitive problems, leading to reverse causality.
Therefore, as depressive symptoms may be due to
different mechanisms, they may have different
odds of progressing towards dementia in people
with MCI. Heterogeneity of depressive symptoms
might also result in different responses to antide-
pressant drugs. It has been shown that depressive
symptoms in MCI are particularly resistant to
treatment.16 For these reasons, it is important to
pay special attention to the time of assessment of
the depressive symptoms when studying the asso-
ciation with MCI and the impact on progression
from MCI to dementia.
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Thirdly, depression as a prodromal feature of cognitive
impairment might have characteristics that do not coincide with
the typical depressive syndrome, as described by depression
interviews, scales and questionnaires. Indeed, isolated depressive
symptoms are common in MCI and low mood is the most
prevalent symptom.1 Moreover, in a recent clinically based
study, low mood predicted progression of MCI to Alzheimer ’s
disease (AD) better than scores from a depression scale.13
Finally, to understand the nature of the relationship between
depressive symptoms and MCI, it is important to unfold the
pattern of interactions with other factors (eg, genetic, psychi-
atric vascular, frailty related and psychosocial) that are relevant
for both depression and MCI and that might modify their
association.
The present paper aimed at investigating the symptom of low
mood as a predictor of MCI and its progression to dementia in
the framework of a large community based study of the elderly,
taking into account: (i) MCI severity, (ii) time of assessment and
(iii) interaction with other factors.
METHODS
Study population
Data were gathered from the Kungsholmen Project, a commu-
nity based prospective study of persons aged 75 years and above,
who lived in Kungsholmen, Stockholm, Sweden, at the end of
1987.22 As illustrated in ﬁgure 1, out of 1700 participants at
baseline (1987e1989) 40 were excluded due to very low global
cognitive status or unknown educational background. To obtain
a cognitively healthy cohort, we further excluded: (a) prevalent
dementia cases (n¼225); and (b) all prevalent MCI cases
(n¼337). Of the remaining 1098 persons, 199 (18%) died and 135
(12%) moved or discontinued their participation before the ﬁrst
follow-up examination. The resulting 764 cognitively healthy
cohort members were followed for 6 years, during which two
clinical examinations took place with an interval of 3 years (ﬁrst
follow-up 1994e1996; second follow-up 1997e1998). To ascer-
tain progression towards dementia, incident MCI cases were
followed for 3 further years (third follow-up 1999e2000).
Between the ﬁrst and the second follow-up examinations, 28
(30%) cases died and six (6%) refused or moved. Between the
second and third follow-up examinations, 23 (35%) cases died
and four (6%) refused or moved.
All phases of the Kungsholmen Project have been approved by
the ethics committee of Karolinska Institutet, and informed
consent was obtained from all participants.
Data collection
All study participants underwent a comprehensive clinical,
medical, cognitive and psychosocial examination both at base-
line and at the follow-ups, as described in detail elsewhere.20 22
Information on medical history was taken from the inpatient
register system which encompasses all hospitals in Stockholm
from 1969 onwards. The International Classiﬁcation of Disease,
8th revision (ICD-8) was used in the register system until
198623; from 1987, the ICD-9th revision (ICD-9) was used.24
Information on drug use (in the preceding 2 weeks) and blood
samples were collected at each examination.
Low mood symptom
We deﬁned the symptom of low mood as a report of perceived
sadness. At baseline, nurses assessed mental health as part of
a general health status interview consisting of questions with
yes/no answers. The questionnaire investigated different health
related symptoms and included items on depressive symptoms,
such as low mood, anxiety, feelings of loneliness, sleeping
disturbances, reduced appetite and tiredness. All of these
symptoms except loss of appetite loaded on the same factor, as
shown by a factor analysis with varimax rotation performed at
baseline. Low mood had the highest loadings on this depression
factor (0.81), followed by feeling lonely (0.70) and anxiety
(0.64).
At the follow-ups, all patients underwent a structured
psychiatric interview performed by physicians and based on the
Comprehensive Psychopathological Rating Scale.25 Report of
perceived sadness was drawn from the Comprehensive Psycho-
pathological Rating Scale interview, and was graded in degree of
severity from 0 (no perceived sadness) to 6 (extreme sadness).26
The item was used both as an ordinal variable and as a categor-
ical variable. In the latter case, the item was dichotomised into
low mood, for all scores exceeding 0, versus no low mood, for
a score equal to 0.
Definition of MCI
People with MCI included all non-demented participants who
fulﬁlled aMCI18 19 or oCIND20 21 criteria. aMCI was deﬁned
according to standard criteria18 19 and operationalised according
to previous research20 as follows: (1) memory complaints were
assessed based on memory problems reported by the subjects or
informants; (2) normal general cognitive function was deﬁned as
scoring above the minus 1 SD cut-off for the age and education
adjusted Mini-Mental State Examination mean (MMSE)27; (3)
absence of dementia was veriﬁed by clinical examination; (4)
normal activities of daily living was characterised by no
impairment in Katz’ Activities of Daily Living scale28; and (5)
objective memory impairment was deﬁned as scoring 1.5 SD
Figure 1 Study population: identification of the cognitively healthy
cohort at baseline with follow-up data. MCI, mild cognitive impairment;
MMSE, Mini-Mental State Examination.
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below the age and education adjusted mean in a verbal memory
task (free recall of slowly and rapidly presented words).29 All
cases with global cognitive impairment that did not fulﬁl criteria
for dementia were classiﬁed as oCIND21 and operationalised
according to previous research20 as follows: (1) impaired general
cognitive function, deﬁned as scoring 1 SD or more below age
and education adjusted means on the MMSE derived from the
dementia free population at baseline; and (2) absence of
dementia, veriﬁed by clinical examination. aMCI and oCIND
were mutually exclusive in the present study.
Diagnosis of dementia
Dementia was diagnosed according to the Diagnostic and
Statistical Manual of Mental Disorders, revised third edition
(DSM-III-R) criteria,30 following a three step procedure, as
described in detail elsewhere.22 The dementia diagnoses for dead
subjects were made by physicians consulting clinical records and
death certiﬁcates.31
In the present study, a broad category, including all dementia
cases, regardless of dementia type, was considered. However, AD
was the most common form of dementia detected, accounting
for nearly 80% of all cases.
Covariates
Medical conditions derived from the inpatient register database
were: history of psychosis (ICD-8 and ICD-9 codes 291e298)
which included episodic mood disorders; history of cerebrovas-
cular disease (ICD-8 and ICD-9 codes 430e438); history of heart
disease (ICD-8 or ICD-9 codes 410e414 and 427e428); hip
fracture (ICD-8 and ICD-9 codes 820, 821); and diabetes (ICD-8
and ICD-9 code 250). Data on diabetes were integrated with
information from other sources, as descried elsewhere.32 High
blood pressure was deﬁned as $180 arterial blood pressure (ie,
systolic Korotkoff phase I and diastolic phase V). Multi-
morbidity was deﬁned as having two or more chronic condi-
tions. Polypharmacy was deﬁned as the use of more than ﬁve
drugs.33 Psychotropic drug use was deﬁned as using one versus
none of the following psychoactive drugs: neuroleptics (ATC
code: N05A), anxiolytics (ATC code: N05B), other tranquilisers,
hypnotics (ATC code: N05C) and antidepressants (ATC code:
N06A). APOE genotyping was carried out using a standard
PCR34 and dichotomised as having at least one ApoE-34 allele
versus having none. Social network was coded according to
previous research as a four level ordinal variable (extensive/
moderate/limited/poor social network).35
Data analysis
Incidence of MCI among cognitively healthy people
The cognitively healthy cohort was followed for 6 years to
detect new cases of MCI. Subjects were considered at risk of
MCI until they: (i) were classiﬁed for the ﬁrst time as MCI or
demented; (ii) dropped out of the study due to refusal or
moving; or (iii) died.
Differences in subject characteristics were tested with Pear-
son’s c2. Independent Cox models were used to estimate the HR
and 95% CIs of developing MCI in relation to baseline low
mood. For cases of MCI detected at the ﬁrst wave of examina-
tions, the baseline for low mood exposure was set at the study
baseline. For cases of MCI detected at the second wave of
examinations, the baseline for low mood exposure was set at the
second wave (ﬁrst follow-up). The relative risks of MCI in
relation to baseline low mood were comparable between the two
waves; therefore, Cox regression analysis was performed using
data from both waves. In order to preserve the 3 year follow-up
exposure for MCI, baseline low mood and all other variables
varying with time were entered as time dependent variables.
Low mood co-occurring with incident MCI (follow-up low
mood) was used as a covariate. Multiplicative interactions were
tested within Cox regression. To test for additive interactions,
the attributable proportion due to interaction was calculated
together with 95% CI.36
Incidence of dementia among cognitively healthy people
Dementia that developed in cognitively healthy people not
previously classiﬁed as MCI was used as a competitive outcome
and the relation with low mood was analysed with the same
methodology described above.
Evolution of MCI
Persons who developed MCI were followed for 3 further years to
assess their progression towards dementia. Independent Cox
regression models were run to evaluate the HR and 95% CI of
dementia in subjects with MCI in relation to baseline and
follow-up low mood. Adjustment and interactions with other
covariates were tested as described above.
Missing values were imputed with Multiple Imputation based
on available information on other covariates,37 using Stata 9.0.
All other analyses were performed using SPSS, with an a level of
p<0.05.
RESULTS
Incidence of MCI among cognitively healthy people
During the 3711.5 person years (minimum 1.2; maximum 8.2) of
follow-up, 160 persons developed MCI. Of these, 40 were clas-
siﬁed as aMCI and 120 as oCIND. Characteristics of the cohort
and the cases are shown in table 1. Fifty-three per cent (n¼21) of
aMCI and 31% (n¼37) of oCIND occurred in people with
baseline low mood. When considering aMCI and oCIND
together, the incidence of MCI in people with baseline low mood
was about 2.5 times higher than that detected among people
without baseline low mood, and this ratio was constant across
the two waves of examinations (ﬁgure 2). Cox regression anal-
ysis performed using data from both waves conﬁrmed the
increased risk of all outcomes in relation to the presence of
baseline low mood although the association was stronger for
aMCI. Adjustment for socioeconomic characteristics and other
covariates, including follow-up low mood, history of psychosis,
psychotropic drug use, ApoE-34 allele, history of cerebrovascular
disease, heart disease, diabetes, high blood pressure, hip fracture,
multimorbidity and polypharmacy, did not substantially change
Table 1 Study population and incident cases of amnestic mild
cognitive impairment, other cognitive impairment no dementia and





aMCI (n[40) oCIND (n[120) All-MCI (n[160)
Age (years), baseline
75e79 367 (48) 19 (48) 61 (51) 80 (50)
80+ 397 (52) 21 (52) 59 (49) 80 (50)
Gender
Women 576 (75) 29 (73) 92 (77) 121 (76)
Men 188 (25) 11 (28) 28 (23) 39 (24)
Education
High 403 (53) 27 (68) 55 (46) 82 (51)
Low 361 (47) 13 (32) 65 (54) 78 (49)
Values are n (%).
All-MCI, overall mild cognitive impairment; aMCI, amnestic mild cognitive impairment;
oCIND, other cognitive impairment no dementia.
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the results and HRs remained stable even after multi-adjustment
(table 2).
Stratiﬁed analyses showed that the increased risk of aMCI and
oCIND associated with baseline low mood was not substan-
tially modiﬁed by follow-up low mood or by the other factors
(as listed above). However, an additive interaction was found
between baseline low mood and ApoE-34 allele for the risk of
developing aMCI (attributable proportion: 0.5, 95% CI 0.1 to
0.96) (ﬁgure 3) but not for the risk of developing oCIND. No
other interactions were observed.
Incidence of dementia among cognitively healthy people
During the follow-up, 158 cognitively healthy persons developed
dementia, bypassing MCI. In these people, the HR for low mood
was 1.6 (95% CI 1.1 to 2.3) after adjustment for age, sex and
education. Further adjustment for the other covariates did not
affect the relationship with baseline low mood. However, the
association was no longer signiﬁcant after adjustment for
follow-up low mood (HR 1.4, 95% CI 0.9 to 2.0) and in the
multi-adjusted model (HR 1.3, 95% CI 0.9 to 1.9).
Evolution of MCI
During the 1354.8 person years (minimum 0.7; maximum 4.5) of
follow-up, 50 people with MCI progressed to dementia. Eleven
cases of dementia occurred in people with aMCI and 39 cases of
dementia occurred in people with oCIND. Among the aMCI
persons who progressed to dementia, eight (70%) had baseline
low mood, detected before the development of aMCI, and three
(27%) had follow-up low mood, which was detected at the time
of aMCI classiﬁcation. Among the oCIND that progressed to
dementia, 14 (33%) had baseline low mood and six (15%) had
follow-up low mood. Cox regression analysis conﬁrmed the
association of baseline low mood with an increased risk of
progression to dementia in people with aMCI (table 3).The
association was strengthened after further adjustment for
ApoE-34 allele. Adjustment for other factors did not substan-
tially change the association. On the other hand, follow-up low
mood was not associated with an increased risk of progression to
dementia in people with aMCI (table 3). Progression to
dementia in people with oCIND was not linked to baseline or
follow-up low mood (table 3).
DISCUSSION
In our large, prospective, community based study, low mood
reported 3 years before MCI detection substantially increased
the risk of developing MCI. In particular, low mood was asso-
ciated with a 5.8-fold increased risk of aMCI, a 2.2-fold increased
risk of oCIND and a 2.7-fold increased risk of all-MCI, after
adjustment for sociodemographic factors. These ﬁndings are in
line with previous evidence from other longitudinal studies
which found an association between baseline depressive symp-
toms and incident MCI, with estimates ranging from 1.2- to
16-fold increased risk of MCI.3e7
The excess risk of aMCI associated with low mood was
almost triple that for oCIND (HR 5.8 vs 2.2), suggesting the
Figure 2 Crude incidence rates (IR) per 1000 person years and 95%
CIs of all mild cognitive impairment in subjects with and without low
mood at baseline. Data are shown for the first and second wave of
examinations separately.
Figure 3 HRs with 95% CIs of amnestic mild cognitive impairment in
relation to ApoE-34 and baseline low mood. Subjects with no low mood
at baseline and without any 34 allele were used as reference. Data are
adjusted for age, sex and education.
Table 2 HRs and 95% CIs of amnestic mild cognitive impairment, other cognitive impairment no
dementia and overall mild cognitive impairment in relation to baseline low mood (3 years before mild
cognitive impairment detection)
aMCI (n[40) oCIND (n[120) All-MCI (n[160)
HR (95% CI) HR (95% CI) HR (95% CI)
Basic adjustment* 5.8 (3.1 to 10.9) 2.2 (1.5 to 3.3) 2.7 (1.9 to 3.7)
Basic adjustment + follow-up LMy 5.5 (2.9 to 10.6) 2.2 (1.5 to 3.3) 2.6 (1.9 to 3.7)
Multi-adjustmentz 6.2 (3.1 to 12.6) 2.2 (1.3 to 3.2) 2.6 (1.8 to 3.7)
*Adjusted for: age, sex, education.
yAdjusted for: age, sex, education and low mood assessed at the same time of MCI detection (follow-up LM).
zSimultaneous adjustment for age, sex, education, history of psychosis, psychotropic drug use, follow-up LM, ApoE-34 allele, history
of cerebrovascular disease, heart disease, diabetes, high blood pressure, hip fracture, multimorbidity and polypharmacy.
All-MCI, overall mild cognitive impairment; aMCI, amnestic mild cognitive impairment; LM, low mood; oCIND, other cognitive
impairment no dementia.
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presence of a gradient in the relationship between low mood and
cognitive impairment severity. Indeed, in our study, the deﬁni-
tion of aMCI excluded people with global cognitive impairment
(MMSE mean 26). On the other hand, oCIND included more
severely impaired cases with global cognitive impairment
(MMSE mean 21) who did not fulﬁl criteria for dementia. In
addition, we also observed a group of people that rapidly
progressed to dementia, bypassing MCI (MMSE mean 8), for
whom the excess risk associated with low mood was 60%, lower
than that observed in both aMCI and oCIND.
Interestingly, we found a synergistic action of low mood and
ApoE-34, with increased risk of aMCI in people with both
baseline low mood and at least one ApoE-34 allele. This is in line
with results from a study on primary care patients5 and
supports the hypothesis that low mood may be related to
AD-type neuropathology.17 38 Conversely, none of the other
factors considered in our investigation interacted with low
mood. In particular, no modiﬁcation of the relationship of
baseline low mood with MCI was observed by taking into
account history of psychosis, psychotropic drug use and vascular
factors. Indeed, low mood in prodromal MCI can be indepen-
dent from history of depression.5 It has also been observed that
depressive symptoms in MCI are particularly resistant to
treatment.16 39 On the other hand, the lack of interaction of low
mood with vascular factors conﬁrms previous ﬁndings from the
Cardiovascular Health Study and does not support the ‘vascular
depression hypothesis’.6
Low mood was associated with a 5.3-fold increased risk of
progression to dementia in people with aMCI. This ﬁnding is in
line with some progression studies of MCI4 12e14 16 and is at
odds with others.8e11 15 Indeed, most of the studies that found
no association or an inverse association focused on depressive
symptoms measured at the same time of MCI detection.8 9 11 15
We showed that only low mood measured at baseline, 3 years
before the detection of MCI, predicted subsequent progression of
MCI to dementia. Conversely, low mood that co-occurred with
MCI did not predict further progression to dementia. This result
supports the hypothesis that the symptom of low mood may be
relevant in the prodromal stage of MCI, losing its importance in
more advanced stages when cognitive deﬁcits are already
manifested. Our ﬁndings do not conﬁrm previous evidence from
a report based on the Religious Order Study10 which found no
increase in depressive symptoms in the prodromal stage of
dementia. Indeed, the generalisability of those results has been
questioned, as religious order people might have higher resilience
against depressive symptoms.40
Our study has many strengths, including the community
based design; the longitudinal assessment of the relationship
between low mood and cognitive impairment; comparison of
the impact of low mood on different types and degrees of
severity of cognitive impairment; comparison of different times
of assessment of low mood in relation to progression of MCI to
dementia; and the thorough assessment of the interaction of low
mood with other factors. However, there are some limitations.
First, it is difﬁcult to disentangle the directionality of the asso-
ciation between low mood and cognitive impairment even in the
framework of a longitudinal study. Reverse causation is always
possible. Indeed, people might have performed poorly in the
cognitive tests because they were depressed at the time of
assessment. This could have generated a spurious association
with baseline low mood if those people with low mood at the
time of MCI detection were already depressed at baseline.
However, we controlled for this possibility and found no
evidence of confounding between baseline low mood and follow-
up low mood. Secondly, the assessment of low mood was
performed in different settings between the ﬁrst and the second
wave of examinations. Nonetheless, the ﬁgures regarding the
occurrence of MCI in relation to low mood at the two
measuring occasions are very similar, pointing to a substantial
stability of the construct of low mood across different
measurements. Thirdly, grading of severity of low mood was not
available for all participants. However, available information
showed that the symptom was mild in most (91%) people with
low mood who developed MCI. Fourthly, the cross sectional
assessment of low mood did not provide any information on
duration. Nonetheless, the majority of people with MCI who
reported low mood at baseline were euthymic on the subsequent
3 year follow-up examination. Fifthly, we used dementia as an
outcome rather than dementia type. This was done considering
the relatively small sample of MCI persons who progressed to
dementia. However, in our population, nearly 80% of all diag-
noses of dementia were classiﬁed as probable or possible AD.
Future investigations should try to expand our ﬁndings using
dementia type as an outcome. Finally, in the present cohort
there was a group of people who developed dementia without
previously being classiﬁed as MCI. It is likely that the associa-
tion between low mood and cognitive decline would have been
further strengthened by using a follow-up interval short enough
to observe the transitional stage of MCI in all subjects who
developed dementia.
Our results showed that low mood is a predictor of MCI
development and its progression towards dementia, and
conﬁrmed our working hypothesis that low mood may be more
closely related to early, rather than advanced, stages of cognitive
decline. There are different possible explanations for this ﬁnding.
One explanation could be that low mood is a risk factor for
cognitive impairment and particularly memory functioning,
which would likely be mediated by the interplay between
psychosocial stress and the activity of the adrenocortico axis,
where imbalance has known effects on neurogenesis and
hippocampal physiology.41 Another possible explanation is that
low mood and MCI share a common neuropathogenic substrate.
In this case, the narrow time frame that we observed for the
relationship between low mood and cognitive decline would be
explained by the stage of the underlying neurodegenerative
process. In earlier stages, when cognitive deterioration is not yet
manifest, low mood could be one behavioural sign of neuro-
degeneration, as in the concept of ‘amyloid-associated
Table 3 HRs and 95% CIs for 3 year progression of amnestic mild
cognitive impairment, other cognitive impairment no dementia and
overall mild cognitive impairment to dementia in relation to low mood
3 years before detection of cognitive impairment (baseline LM) and to
low mood reported at the time of detection of cognitive impairment
(follow-up LM)
Dementia (n[50)
HR (95% CI) for
baseline LM
HR (95% CI) for
follow-up LM
aMCI Basic adjustment* 5.3 (1.2 to 23.3) 1.2 (0.3 to 5.2)
Basic + ApoE-34y 5.9 (1.4 to 25.0) 1.1 (0.5 to 2.0)
oCIND Basic adjustment* 1.1 (0.5 to 2.1) 1.0 (0.5 to 2.1)
Basic + ApoE-34y 1.0 (0.5 to 2.1) 1.1 (0.5 to 2.3)
All-MCI Basic adjustment* 1.4 (0.8 to 2.4) 1.0 (0.5 to 2.0)
Basic + ApoE-34y 1.4 (0.8 to 2.4) 1.1 (0.5 to 2.0)
*Adjusted for: age, sex, education.
yAdjusted for: age, sex, education and ApoE-34 allelic status.
All-MCI, overall mild cognitive impairment; aMCI, amnestic mild cognitive impairment; LM,
low mood; oCIND, other cognitive impairment no dementia.
Caracciolo B, Ba¨ckman L, Monastero R, et al. J Neurol Neurosurg Psychiatry (2010). doi:10.1136/jnnp.2010.225003 5 of 6
Research paper
depression’.17 In more advanced stages, when neurodegeneration
has become more pervasive, MCI could represent a later mani-
festation of the process leading to dementia.
In conclusion, although further studies are needed to disen-
tangle the relative contribution of possible underlying mecha-
nisms, cognitively healthy elderly subjects presenting with the
symptom of low mood should be closely monitored as they are
at increased risk of MCI and subsequent progression to
dementia.
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